BigHat Biosciences inks $75m Series B

• The other investors included Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels and GRIDS Capital
• Section 32 Managing Partner Andy Harrison will join BigHat as a board observer
• BigHat was founded in 2019

San Mateo, California-based BigHat Biosciences, a biotechnology company, has raised $75 million in Series B funding. Section 32 led the round with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, among others.

Prior investors Andreessen Horowitz, 8VC, and AME Cloud Ventures also contributed to this round. Cooley advised BigHat on the financing.

“BigHat is ushering the next wave of personalized medicines with a sophisticated AI platform integrated with a next-generation lab that addresses the complexities and inefficiencies associated with biologics discovery,” said Steve Kafka, PhD, managing partner of Section 32 and newly-appointed BigHat board member, in a statement. “Section 32 is delighted to support BigHat’s mission and their quest to rapidly deliver safer and more effective antibody therapies for people suffering from today’s most challenging diseases.”

Longtime Alphabet executive and Section 32 Managing Partner Andy Harrison co-led this Series B financing and will join as a board observer

BigHat was founded in 2019 by CEO Mark DePristo, a University of Cambridge biochemistry Ph.D., former head of Genomics for Google.AI, and co-director of Medical Genetics at Broad Institute, with CSO Peyton Greenside, a Stanford biomedical informatics Ph.D. and 2018 Schmidt Science Fellow.

To date, BigHat has raised $105 million from top investors led by Section 32, Andreessen Horowitz, and 8VC.